The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
Open accessAbstract
UNLABELLED: The expression status of human epidermal growth factor receptor type 2 (HER2) predicts the response of HER2-targeted therapy in breast cancer. ABY-025 is a small reengineered Affibody molecule targeting a unique epitope of the HER2 receptor, not occupied by current therapeutic agents. This study evaluated the distribution, safety, dosimetry, and efficacy of (111)In-ABY-025 for determining the HER2 status in metastatic breast cancer. METHODS: Seven patients with metastatic breast cancer and HER2-positive (n = 5) or -negative (n = 2) primary tumors received an intravenous injection of approximately 100 μg (∼ 140 MBq) of (111)In-ABY-025. Planar γ-camera imaging was performed after 30 min, followed by SPECT/CT after 4, 24, and 48 h. Blood levels of radioactivity, antibodies, shed serum HER2, and toxicity markers were evaluated. Lesional HER2 status was verified by biopsies. The metastases were located by (18)F-FDG PET/CT 5 d before (111)In-ABY-025 imaging. RESULTS: Injection of (111)In-ABY-025 yielded a mean effective dose of 0.15 mSv/MBq and was safe, well tolerated, and without drug-related adverse events. Fast blood clearance allowed high-contrast HER2 images within 4-24 h. No anti-ABY-025 antibodies were observed. When metastatic uptake at 24 h was normalized to uptake at 4 h, the ratio increased in HER2-positive metastases and decreased in negative ones (P < 0.05), with no overlap and confirmation by biopsies. In 1 patient, with HER2-positive primary tumor, (111)In-ABY-025 imaging correctly suggested a HER2-negative status of the metastases. The highest normal-tissue uptake was in the kidneys, followed by the liver and spleen. CONCLUSION: (111)In-ABY-025 appears safe for use in humans and is a promising noninvasive tool for discriminating HER2 status in metastatic breast cancer, regardless of ongoing HER2-targeted antibody treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Dijkers, E. C., Oude Munnink, T. H., Kosterink, J. G., Brouwers, A. H., Jager, P. L., de Jong, J. R., van Dongen, G. A., Schröder, C. P., Lub-de Hooge, M. N., & de Vries, E. G. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.12 · Cited by 805
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kaufman, P. A., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0868 · Cited by 717
Löfblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J., Ståhl, S., & Frejd, F. Y. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.04.014 · Cited by 651
Self-citationTumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule
Orlova, A., Magnusson, M., Eriksson, T. L. J., Nilsson, M., Larsson, B., Höidén-Guthenberg, I., Widström, C., Carlsson, J., Tolmachev, V., Ståhl, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3521 · Cited by 568
Self-citationNiikura, N., Liu, J., Hayashi, N., Mittendorf, E. A., Gong, Y., Palla, S. L., Tokuda, Y., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Ueno, N. T. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8889 · Cited by 410
Targeted therapies for breast cancer
Higgins, M. J., & Baselga, J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57152 · Cited by 369
Perik, P. J., Lub-De Hooge, M. N., Gietema, J. A., van der Graaf, W. T. A., de Korte, M. A., Jonkman, S., Kosterink, J. G. W., van Veldhuisen, D. J., Sleijfer, D. T., Jager, P. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8448 · Cited by 310
Baum, R. P., Prasad, V., Müller, D., Schuchardt, C., Orlova, A., Wennborg, A., Tolmachev, V., & Feldwisch, J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.073239 · Cited by 308
Self-citationTargeted Therapy in Breast Cancer
Ross, J. S., Fletcher, J. A., Bloom, K. J., Linette, G. P., Stec, J., Symmans, W. F., Pusztai, L., & Hortobagyi, G. N. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r400001-mcp200 · Cited by 303
Sequential Versus Concurrent Trastuzumab in Adjuvant Chemotherapy for Breast Cancer
Perez, E. A., Suman, V. J., Davidson, N. E., Gralow, J. R., Kaufman, P. A., Visscher, D. W., Chen, B., Ingle, J. N., Dakhil, S. R., Zujewski, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.7045 · Cited by 255
Cortés, J., Fumoleau, P., Bianchi, G. V., Petrella, T. M., Gelmon, K., Pivot, X., Verma, S., Albanell, J., Conte, P., Lluch, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4207 · Cited by 249
Structural basis for high-affinity HER2 receptor binding by an engineered protein
Eigenbrot, C., Ultsch, M., Dubnovitsky, A., Abrahmsén, L., & Härd, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005025107 · Cited by 233
Orlova, A., Tolmachev, V., Pehrson, R., Lindborg, M., Tran, T., Sandström, M., Nilsson, F. Y., Wennborg, A., Abrahmsén, L., & Feldwisch, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2887 · Cited by 193
Self-citationDesign of an Optimized Scaffold for Affibody Molecules
Feldwisch, J., Tolmachev, V., Lendel, C., Herne, N., Sjöberg, A., Larsson, B., Rosik, D., Lindqvist, E., Fant, G., Höidén-Guthenberg, I., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.03.002 · Cited by 181
Self-citationKramer-Marek, G., Kiesewetter, D. O., Martiniova, L., Jagoda, E., Lee, S. B., & Capala, J. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0658-0 · Cited by 160
Houssami, N., Macaskill, P., Balleine, R. L., Bilous, M., & Pegram, M. D. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1632-x · Cited by 116
Ahlgren, S., Orlova, A., Wållberg, H., Hansson, M., Sandström, M., Lewsley, R., Wennborg, A., Abrahmsén, L., Максимилианович, Т. В., & Feldwisch, J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.073346 · Cited by 97
Self-citationМаксимилианович, Т. В., Tran, T. A., Rosik, D., Sjöberg, A., Abrahmsén, L., & Orlova, A. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.101527 · Cited by 94
Recent advances in novel targeted therapies for HER2-positive breast cancer
Murphy, C. G., & Morris, P. G. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328352d292 · Cited by 72
When to order a biopsy to characterise a metastatic relapse in breast cancer
Foukakis, T., Åström, G., Lindström, L. S., Hatschek, T., & Bergh, J. C. S. (2012) · Annals of Oncology · doi:10.1093/annonc/mds297 · Cited by 55
Self-citationNew therapies in HER2-positive breast cancer: A major step towards a cure of the disease?
Awada, A. H., Božović‐Spasojević, I., & Chow, L. W. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.01.001 · Cited by 46
Krämer-Marek, G., Gijsen, M., Kiesewetter, D. O., Bennett, R., Roxanis, I., Zieliński, R., Kong, A. H., & Capala, J. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.096685 · Cited by 38
Patients with anti-HER2 responsive disease: definition and adjuvant therapies
Burstein, H. J. (2011) · The Breast · doi:10.1016/s0960-9776(11)70310-1 · Cited by 5
Cited by
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Radioactive Main Group and Rare Earth Metals for Imaging and Therapy
Kostelnik, T. I., & Orvig, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00294 · Cited by 483
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
Keyaerts, M., Xavier, C., Heemskerk, J., Devoogdt, N., Everaert, H., Ackaert, C., Vanhoeij, M., Duhoux, F. P., Gevaert, T., Simon, P., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.162024 · Cited by 429
Affibody Molecules in Biotechnological and Medical Applications
Ståhl, S., Gräslund, T., Eriksson Karlström, A., Frejd, F. Y., Nygren, P.-Å., & Löfblom, J. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2017.04.007 · Cited by 382
Bridging Bio–Nano Science and Cancer Nanomedicine
Björnmalm, M., Thurecht, K. J., Michael, M., Scott, A. M., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b04855 · Cited by 382
Metadata
- Authors
- Sörensen, J., Sandberg, D., Sandström, M., Wennborg, A., Feldwisch, J., Tolmachev, V., Åström, G., Lubberink, M., Garske-Román, U., Carlsson, J., & Lindman, H.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2014-03-24
- Volume
- 55
- Issue
- 5
- Pages
- 730-735
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2132840811
- Cited by
- 258
- References
- 27
- FWCI
- 22.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.